Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
IOBT IO Biotech
2.820+0.030+1.08%
Close
01/27 16:00 ET
High
2.904
Open
2.740
Turnover
62.28K
Low
2.740
Pre Close
2.790
Volume
21.89K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Morgan Stanley Adjusts Price Target on IO Biotech to $11 From $15, Maintains Overweight Rating
11:35 AM EST, 01/24/2023 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may co
Morgan Stanley Reaffirms Their Buy Rating on IO Biotech (IOBT)
IO Biotech Price Target Cut to $11.00/Share From $15.00 by Morgan Stanley
IO Biotech Is Maintained at Overweight by Morgan Stanley
Morgan Stanley Maintains Overweight on IO Biotech, Lowers Price Target to $11
Morgan Stanley analyst Matthew Harrison maintains IO Biotech with a Overweight and lowers the price target from $15 to $11.
IO Biotech Appoints Smith as General Counsel, Chief Compliance Officer
IO Biotech Announces Appointment of Devin Smith as General Counsel
NEW YORK, Jan. 23, 2023 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® vaccine platform, today
IO Biotech Ended 2022 With ~$142.7M In Cash And Cash, Anticipates This Will Be Sufficient To Fund Operations Into Mid-2024
IO Biotech Ended 2022 With ~$142.7M In Cash And Cash, Anticipates This Will Be Sufficient To Fund Operations Into Mid-2024
IO Biotech Provides Business Update
Analyst Says IO Biotech's Cancer Treatment Approach 'Differentiated'
HC Wainwright has initiated coverage on Denmark-based cancer firm IO Biotech Inc (NASDAQ:IOBT) with a Buy rating and a price target of $10.The company's T-win platform works through a dual mechanism o
Company Overview
More
IO Biotech, Inc. engages in the development of immune modulating cancer therapies based on its T-win technology platform. Its platform is a novel approach to cancer immunotherapy designed to activate naturally occurring T cells to target immunosuppressive mechanisms. The company was founded by Mai-Britt Zocca, Inge Marie Svane, and Mads Hald Andersen in December 2014 and is headquartered in Copenhagen, Denmark.
CEO： Dr. Mai-Britt Zocca, PhD
Market： NASDAQ
Listing Date： 11/05/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet